How MOTS-c Activates AMPK and Insulin Sensitivity
MOTS-c
5-fold AICAR Increase
MOTS-c blocks the folate cycle, causing endogenous AICAR to accumulate and activate AMPK, the cell's master energy sensor that drives glucose uptake.
Lee et al., Cell Metabolism, 2015
Lee et al., Cell Metabolism, 2015
View as imageA 16-amino-acid peptide encoded in mitochondrial DNA can activate the same energy-sensing pathway that metformin and exercise both trigger. MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) was discovered in 2015 by Lee et al., who showed it prevents diet-induced obesity and insulin resistance in mice through AMPK activation.[1] The mechanism is specific: MOTS-c inhibits the folate cycle, causing the AMPK activator AICAR to accumulate inside cells. That single metabolic disruption cascades into improved glucose uptake, enhanced fatty acid oxidation, and restored insulin signaling in skeletal muscle. For a broader overview of this peptide, see MOTS-c: the mitochondrial peptide that mimics exercise.
Key Takeaways
- Lee et al. (2015) discovered MOTS-c activates AMPK by inhibiting the folate cycle, causing a 5-fold increase in endogenous AICAR levels in treated cells[1]
- Kim et al. (2019) showed MOTS-c treatment enhanced insulin sensitivity in both aged and high-fat-diet mice, with treated animals showing glucose handling equivalent to lean controls[4]
- Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus to regulate genes with antioxidant response elements (Kim et al., 2018)[3]
- Yang et al. (2021) found MOTS-c combined with exercise produced synergistic AMPK activation and PGC-1-alpha expression beyond either intervention alone[8]
- Reynolds et al. (2021) demonstrated that exercise increases endogenous MOTS-c levels in human skeletal muscle and plasma, with levels declining in aging[5]
- Gudiksen et al. (2026) confirmed MOTS-c improves intrinsic muscle mitochondrial bioenergetics through a PGC-1-alpha/AMPK-dependent mechanism[10]
The Folate-AICAR-AMPK Pathway
The central mechanism of MOTS-c action runs through a three-step metabolic cascade. Understanding each step explains why this small peptide produces such broad metabolic effects.
Step 1: Folate Cycle Inhibition
MOTS-c inhibits the folate cycle at the level of 5-methyltetrahydrofolate (5Me-THF). Lee et al. (2015) showed that MOTS-c treatment reduced 5Me-THF levels first, before any downstream metabolic changes appeared.[1] The folate cycle normally provides one-carbon units for de novo purine biosynthesis. When MOTS-c blocks this cycle, the purine synthesis pathway stalls at a specific intermediate.
Step 2: AICAR Accumulation
That intermediate is AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). With de novo purine biosynthesis blocked, AICAR accumulates inside the cell. Lee et al. measured approximately a 5-fold increase in endogenous AICAR levels in MOTS-c-treated cells.[1] AICAR is a well-characterized AMPK activator that has been studied independently as an exercise-mimetic compound. For more on AICAR's direct effects, see AICAR and endurance enhancement.
Step 3: AMPK Activation
AICAR activates AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK monitors the AMP-to-ATP ratio and switches on catabolic pathways (glucose uptake, fatty acid oxidation) while switching off anabolic ones (lipogenesis, gluconeogenesis) when cellular energy is low. Wan et al. (2023) described this folate-AICAR-AMPK axis as the primary mechanism through which MOTS-c influences energy metabolism, insulin sensitivity, and stress adaptation.[6]
The downstream effects of AMPK activation by MOTS-c include:
- GLUT4 translocation: AMPK phosphorylation drives glucose transporter 4 (GLUT4) to the cell membrane in skeletal muscle, increasing glucose uptake independent of insulin signaling
- Fatty acid oxidation: AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC), removing the brake on mitochondrial fatty acid import and oxidation
- PGC-1-alpha activation: AMPK activates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1-alpha), the master regulator of mitochondrial biogenesis
What Happens in Skeletal Muscle
Skeletal muscle is the primary target tissue for MOTS-c's insulin-sensitizing effects. This makes physiological sense: skeletal muscle accounts for approximately 80% of insulin-stimulated glucose disposal.
Lee et al. (2016) characterized MOTS-c's effects on muscle and fat metabolism, showing that the peptide activates AMPK specifically in skeletal muscle cells and redirects glucose metabolism.[2] The glucose taken up in response to MOTS-c was routed to the pentose phosphate pathway (PPP) rather than glycolysis. The PPP generates NADPH for antioxidant defense and ribose-5-phosphate for nucleotide synthesis, suggesting MOTS-c shifts muscle metabolism toward biosynthetic and protective functions rather than pure energy extraction.
Kim et al. (2019) tested MOTS-c's metabolic effects using unbiased metabolomics in diet-induced obese mice. Three weeks of daily MOTS-c injections (15 mg/kg) reversed metabolic dysfunction: treated mice showed plasma metabolite profiles closer to lean controls than to untreated obese mice. Sphingolipid and monoacylglycerol metabolism were among the pathways most strongly affected, both of which are implicated in insulin resistance.[4]
Gudiksen et al. (2026) provided the most recent mechanistic data. In mice treated with MOTS-c, intrinsic muscle mitochondrial bioenergetic health improved through a PGC-1-alpha/AMPK-dependent mechanism. The effect was specific to mitochondrial efficiency rather than simply increasing mitochondrial number, suggesting MOTS-c improves the quality of existing mitochondria rather than only driving biogenesis.[10]
The Nuclear Translocation Discovery
In 2018, Kim et al. made a finding that changed how researchers understood MOTS-c: under metabolic stress, the peptide physically moves from mitochondria to the nucleus.[3] This was the first demonstration that a mitochondrial-encoded factor actively regulates nuclear gene expression.
Inside the nucleus, MOTS-c interacts with transcription factors and binds to promoter regions containing antioxidant response elements (AREs). This means MOTS-c does not only work through AMPK. It directly modifies which genes the cell expresses when under metabolic pressure, upregulating stress-response and antioxidant genes. Kim et al. showed this nuclear translocation occurs in response to glucose restriction, oxidative stress, and serum deprivation, all conditions that cells encounter during metabolic disease.
This dual mechanism, AMPK activation in the cytoplasm and direct gene regulation in the nucleus, distinguishes MOTS-c from other AMPK activators like metformin or AICAR, which work only through AMPK and its downstream kinase cascades.
MOTS-c and Exercise: Synergistic AMPK Activation
Exercise is the most potent known AMPK activator in skeletal muscle. MOTS-c appears to work through a convergent pathway, and the two interventions produce additive or synergistic effects.
Reynolds et al. (2021) published the first evidence that MOTS-c is an exercise-induced peptide in humans. In skeletal muscle biopsies from young men after acute exercise, MOTS-c levels increased in the muscle tissue. Plasma MOTS-c also rose after exercise. In aging mice (22-23 months old), MOTS-c treatment improved physical capacity on the treadmill, with treated mice running significantly longer than untreated controls. The effect was AMPK-dependent.[5]
Yang et al. (2021) tested MOTS-c combined with exercise in insulin-resistant mice fed a high-fat diet. The combination activated the AMPK/PGC-1-alpha pathway more strongly than either intervention alone, producing synergistic improvements in insulin sensitivity and glucose metabolism. Critically, MOTS-c also upregulated its own expression through a feedback loop: AMPK activation increased PGC-1-alpha, which in turn stimulated mitochondrial gene expression, including the 12S rRNA region that encodes MOTS-c itself.[8] This positive feedback loop may explain why regular exercise progressively improves insulin sensitivity over time: each bout of exercise increases MOTS-c production, which amplifies AMPK signaling, which drives further MOTS-c expression. For context on how peptides interact with exercise, see MOTS-c and physical performance.
Insulin Resistance Models: Obesity, Aging, and Gestational Diabetes
Diet-Induced Obesity
The original Lee et al. (2015) study demonstrated that MOTS-c prevents obesity and insulin resistance when administered to mice fed a high-fat diet. Mice receiving daily MOTS-c injections (5 mg/kg) gained less weight, had lower fasting glucose, and showed improved glucose tolerance compared to controls. The effects were mediated through skeletal muscle AMPK activation and GLUT4 upregulation.[1]
Age-Related Insulin Resistance
Reynolds et al. (2021) showed that endogenous MOTS-c levels decline with age in both mice and humans, which may contribute to age-related insulin resistance. In aged mice, exogenous MOTS-c restored physical capacity and improved metabolic parameters to levels approaching those of younger animals.[5] The age-related decline in MOTS-c parallels the well-documented decline in mitochondrial function and insulin sensitivity with aging. For a deeper look at the aging connection, see MOTS-c and aging.
Gestational Diabetes
Yin et al. (2022) tested MOTS-c in a mouse model of gestational diabetes mellitus (GDM). MOTS-c treatment significantly alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, and reduced birth weight abnormalities in offspring. The mechanism involved increased phosphorylation of AMPK and AKT and upregulation of GLUT4 in skeletal muscle, the same pathway documented in the obesity models. MOTS-c mainly accumulated in the pancreas and intestine, with lower concentrations in skeletal muscle, liver, kidney, and spleen.[9]
How MOTS-c Compares to Other AMPK Activators
Several compounds activate AMPK, but they differ in mechanism and specificity:
- Metformin: inhibits mitochondrial complex I, increasing the AMP/ATP ratio. This activates AMPK indirectly. Metformin has poor tissue specificity and causes gastrointestinal side effects in approximately 25% of patients. For a comparison of metformin and peptide-based approaches, see GLP-1 vs metformin.
- AICAR: directly activates AMPK as an AMP mimetic. However, exogenous AICAR has poor oral bioavailability and broad tissue effects that make it impractical as a therapeutic.
- Exercise: activates AMPK through energy depletion (increased AMP/ATP ratio) during muscle contraction. The most physiological activator but requires physical capacity.
- MOTS-c: activates AMPK specifically through the folate-AICAR pathway, producing endogenous AICAR accumulation rather than delivering an exogenous AMPK activator. Additionally, MOTS-c has the nuclear translocation mechanism that other AMPK activators lack.
The key distinction is that MOTS-c does not simply turn on AMPK. It reconfigures cellular metabolism at the level of one-carbon metabolism (folate cycle) while simultaneously entering the nucleus to regulate stress-response genes. This multi-layered action may explain why MOTS-c produces effects beyond what AMPK activation alone would predict.
Limitations of the Current Evidence
All MOTS-c insulin sensitivity studies to date are preclinical. No randomized controlled trial has tested MOTS-c in human patients with diabetes or insulin resistance. The mouse data is compelling but uses supraphysiological doses (5-15 mg/kg/day) that may not translate directly to human dosing.
The folate cycle inhibition mechanism raises questions about long-term safety. Folate is essential for DNA synthesis and methylation. Chronic inhibition of the folate cycle could theoretically impair cell division in rapidly turning over tissues (gut epithelium, bone marrow), though this has not been observed in the animal studies published to date.
Endogenous MOTS-c levels have been measured in human plasma (Reynolds et al., 2021) and shown to correlate with exercise and decline with age, but the absolute plasma concentrations are in the nanomolar range.[5] Whether exogenous MOTS-c administration in humans would achieve tissue concentrations sufficient for AMPK activation remains untested.
The relationship between MOTS-c and mitochondrial DNA haplogroups also introduces genetic variability. Different mtDNA haplogroups encode slightly different MOTS-c sequences, which may affect peptide activity. Lee et al. (2015) noted that a common m.1382A>C polymorphism in East Asian populations alters the MOTS-c sequence. Whether this variant has different AMPK-activating potency is unknown.[1]
Zheng et al. (2023) reviewed the full landscape of MOTS-c research and emphasized that while the folate-AICAR-AMPK pathway is well-established in cell culture and mouse models, the peptide's pharmacokinetics, tissue distribution, and dose-response relationship in humans remain uncharacterized.[7]
The Bottom Line
MOTS-c activates AMPK through a specific mechanism: inhibition of the folate cycle causes AICAR accumulation, which phosphorylates and activates AMPK in skeletal muscle. This drives GLUT4 translocation, enhanced glucose uptake, and fatty acid oxidation. Under metabolic stress, MOTS-c also translocates to the nucleus to regulate antioxidant genes directly. Animal studies show restored insulin sensitivity in obese, aged, and gestational diabetes models, and exercise increases endogenous MOTS-c levels. No human clinical trials have been completed. The age-related decline in MOTS-c production may contribute to the progressive insulin resistance seen in aging.